AstraZeneca Signs an Agreement with Gatehouse Bio to Identify New Therapies Targeting Respiratory and Cardiovascular Diseases

Shots:

• AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform
• The collaboration allows Gatehouse Bio to develop next-generation therapies and epitomizes its focus on Bio Hub Incubator. In 2018, Gatehouse Bio joined AstraZeneca’s Boston Bio Hub Incubator to accelerate their research and developed pipeline of RNA sequencing with biology-influenced ML algorithms after 18mos.
• Gatehouse Bio’s sRNAlytics platform highlights molecular pathways of diseases via analyses of small RNA, then insights are converted to therapeutic targets and CDx

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Times